

Vax CAB 2023 roadmap

Mission

Ensure equitable global access to better vaccines.

Vision

A world where everyone has access to the most effective preventive tools to live a healthy life.

Who we are

in June 2021, at the start of the COVID-19 outbreak, AVAC and ITPC joined efforts to create the COVID-19 Advocates' Advisory Board Meetings on Vaccines (CAB Vax), a forum for advocates to tackle issues around COVID-19 vaccine access while ensuring communities are meaningfully involved.

Currently, the group has evolved into the Vaccine Community Advisory Board (Vax CAB). The aim of the Vax CAB is to create a forum to facilitate dialogue with vaccine manufacturers, international organizations, national and regional authorities, governments, and other stakeholders to ensure global vaccine equity. The Vax CAB is also a space to build the capacity of communities in the areas of vaccine development, technology transfer, registration, manufacturing, distribution, access plans, and products in the pipeline. These skills and capacities may also allow for advocacy actions as CAB Vax and within the communities the members represent/ work with.

Although the Vax CAB resembles other CABs in its quest to set the research agenda, its hallmark is its focus on vaccine access. In this field, the training on IP and trade barriers, the promotion of technology transfers and the encouragement of local production are key to the work and mission of the CAB. The Vax CAB aims to build capacity for, and stimulate advocacy around local production, tech transfer, removal of IP and registration barriers, among other topics.

As Vax CAB enters 2023, we aim to strengthen our internal capacity, widen our vaccine work beyond COVID-19 and develop a more robust advocacy agenda.

Advocacy

1. Involve civil society in R&D prioritization and clinical trial design
2. Remove all barriers that block access to vaccines (IP, manufacturing, delivery, registration, etc.)
3. Encourage local production of vaccines

Activities

1. Capacity-building and technical assistance.
2. Knowledge exchange (national, regional, international updates)
3. Organize meetings with key stakeholders (originators, local manufacturers, universities, government bodies, international agencies, etc.).

4. Design and implement advocacy campaigns with clear actions, audiences and deliverables.
5. Engage with and support regional and thematic CABs for cross-learning, synergies and joint-campaigns.

Area focus

1. COVID-19, tuberculosis, malaria, HIV, monkeypox and any emerging health threats.
2. Cross-cutting issues related to technology transfer, advocacy for local production of mRNA and other vaccines.
3. Policy.

Geographic scope

National, regional, international

Next steps

1. Vote or comments on the above items by current CAB.
2. Vaccine policy suggestion from Kajal (linked to capacity building and network?).
3. Call for applications for next CAB.
4. Develop communications tools (listserv, etc.).
5. Develop advocacy materials to support campaigns.